Target intelligence / Profile preview

microRNA 617 (miR-617)

Target
miR-617
Molecular classification
microRNA, Noncoding RNA, Gene regulator (miRNAs are classified as small noncoding RNAs functioning in gene regulation)
01

Overview

microRNA 617 (miR-617) is a small, noncoding RNA of the microRNA family that regulates gene expression post-transcriptionally and, unusually, can also activate gene transcription by binding gene promoters. miR-617 is coded within an intron and has its own promoter region. In cancer biology, particularly oral squamous cell carcinoma, miR-617 is downregulated via promoter hypermethylation. Experimentally, miR-617 upregulates the DDX27 gene by a novel promoter-interacting mechanism, suppresses cell proliferation, and promotes apoptosis. The PI3K/AKT/MTOR signaling pathway is modulated downstream of the miR-617/DDX27 axis. Advances in understanding its pathway have highlighted miR-617 and its mimics as promising therapeutic targets and potential biomarkers for cancer, though specificity and therapeutic delivery remain significant challenges.

Other names
MIR617hsa-mir-617MIRN617
02

Mechanism of action

Gene reactivation via promoter hypomethylation (e.g., 5-Azacytidine upregulates miR-617 by demethylating its promoter); miRNA mimic action (synthetic miRNAs can restore or modulate biological functions; for miR-617, mimics demonstrate anti-proliferative and pro-apoptotic effects in OSCC)

03

Biological functions

Gene expression regulation (miRNAs control mRNA stability and translation)Cell proliferation regulation (miR-617 downregulates cell proliferation in oral squamous cell carcinoma, OSCC)Apoptosis modulation (miR-617 positively regulates apoptosis in OSCC)Transcriptional activation (miR-617 can activate protein-coding genes by binding to gene promoters—specifically DDX27)Signal transduction (impacts the PI3K/AKT/MTOR pathway via its effects on DDX27)
04

Disease associations

Cancer (specifically oral squamous cell carcinoma: downregulation and aberrant expression is associated with cancer development and progression)Other potential roles in cancer (miRNAs broadly implicated in tumor suppression and oncogenesis)
05

Safety considerations

Therapeutic specificity (as with all miRNA therapeutics, off-target effects and the complexity of miRNA targets present challenges)Drug delivery (ensuring specific and efficient delivery of miR-617 mimics or modulators in vivo remains a general challenge for miRNA-based therapies)Epigenetic modulator effects (drugs like 5-Azacytidine act broadly on DNA methylation and may affect many genes, not just miR-617)
06

Interacting drugs

Synthetic miR-617 mimics (proposed for cancer therapy based on experimental studies)

1 more in the full profile.

07

Biomarkers

miR-617 expression status (low levels are associated with OSCC; recovery of expression could indicate response to specific treatments)DDX27 levels (as the regulatory axis involving miR-617 and DDX27 is implicated in disease progression and therapeutic response)

Beyond the preview

Go deeper on microRNA 617 (miR-617).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA 617 (miR-617).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call